Diasome Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Diasome Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials none currently recruiting 6 completed early-phase tilt upper quartile by trial count

Diasome Pharmaceuticals: 6 sponsored US clinical trials, none currently recruiting.

Diasome Pharmaceuticals sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetes Mellitus, Type 1, with 1 trials.

Upper-quartile sponsor footprint

Diasome Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

6 total, page 1 of 1

COMPLETED Phase 2

Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec

NCT03938740
COMPLETED Phase 2

21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus

NCT03156361
COMPLETED Phase 2

Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control

NCT03096392
COMPLETED Phase 2

Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)

NCT02794155
COMPLETED Phase 2

Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus

NCT00814294
COMPLETED

A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus

NCT00521378

Phase Distribution

PhaseTrial count
Phase 2 5

Therapeutic Areas

Diabetes Mellitus, Type 1 1

How the Diasome Pharmaceuticals early-phase archive is shaped

6 indexed studies, none listed as recruiting (0% open); 6 completed (100%).

Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Diabetes Mellitus, Type 1 (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Diasome Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Diasome Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share Diasome Pharmaceuticals23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan Branch10xBio22nd Century Group3-C Institute for Social Development3 Waves Wellness
Diasome Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Diasome Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Diasome Pharmaceuticals page

6 registered trials is a research-attention snapshot, not an endorsement of Diasome Pharmaceuticals or any single study.

  • None of Diasome Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Diabetes Mellitus, Type 1 is the condition Diasome Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes Mellitus, Type 1 trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Diasome Pharmaceuticals pipeline card: 6 registered trials from official public datasets.Report a data error.